Cristal Therapeutics announces a publication in ‘Chemical Science’ on CliCr® technology platform, comprising a new class of superior copper free click reagents for conjugation of small molecules, biologics, nanoparticles and other moieties

• Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent • Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development • CliCr® can be...

Synaffix wins Best Platform Technology at 7th Annual World ADC Awards

AMSTERDAM, NETHERLANDS – September 22, 2020 – Synaffix B.V., a biotechnology companyenabling antibody-drug conjugates (ADCs) with best-in-class therapeutic index, announces thatit has won the “Best ADC Platform Technology” category at the 2020 World ADC...

Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech

● Multi-year strategic collaboration in target discovery and therapeutic developmentbased on Scenic Biotech’s disease modifying approach● Utilises Scenic’s unique Cell-Seq platform and its proprietary data warehouse ofgenetic modifiers● Scenic Biotech will receive an...

Synaffix Announces Expansion of Collaboration with ADC Therapeutics

AMSTERDAM, NETHERLANDS – July 23, 2020 – Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology platform, announces that ADC Therapeutics SA has expanded its...